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Recombinant human erythropoietin (rHuEPO) is detected by using direct pharmacological assays and 
indirect haematological assays. However, both methods have several limitations including technical 
challenges and cost-related issues. The aim of this study was to develop polyclonal antibodies against 
rHuEPO (anti-rHuEPO pAb) that can be used in immunoassays. In this study, we purified anti-rHuEPO 
pAb that could be used in immunoblotting assays to efficiently detect rHuEPO. Furthermore, these anti-
rHuEPO pAb which could also detect rHuEPO that was expressed in a eukaryotic expression system 
(CHO cells). Thus, the anti-rHuEPO pAb developed in this study may be useful for rHuEPO detection. 
 





Erythropoietin (EPO) is a glycoprotein hormone that is 
responsible for the homeostatic regulation of red blood 
cell production, and consequently increases tissue oxy-
genation (Lacombe and Mayeux, 1998). Human recom-
binant erythropoietin (rHuEPO) has been successfully 
produced in mammalian cells cultures since the late 
1980s and has several therapeutic applications such as 
the treatment of anaemia and polycythemia in patients 
having chronic kidney disease, acquired 
immunodeficiency syndrome (AIDS) and cancer 
(Macdougall and Ashenden, 2009). rHuEPO was used as 
a performance enhancement drug by athletes partici-
pating in endurance sports, has therefore been banned 
by the World Anti-Doping Agency since 1990 (Reichel 
and Gmeiner, 2010). Thus, rHuEPO detection methods 
are used for evaluating blood doping and for disease
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diagnosis. The increased availability of biosimilars and 
uncontrolled drugs has resulted in a need for the 
development of reliable rHuEPO detection methods 
(Girard et al., 2012). 
The rHuEPO detection assays either use a direct 
pharmacological approach, or an indirect haematological 
approach. However, both methods have several 
limitations (Diamanti-Kandarakis et al., 2005) including 
technical challenges and cost-related issues (Azzazy et 
al., 2005). Recently, several rHuEPO assays were 
developed for studying the pathophysiology of anaemia 
and polycythemia (Lonnberg et al., 2012). Immunoassays 
that use antibodies against rHuEPO have been 
immensely useful for studying the structure/function of 
EPO and for the sensitive detection of EPO in biological 
fluids (Bornemann et al., 2003; Mi et al., 2005; Sytkowski 
and Fisher, 1985; Wang et al., 2003). 
Cell lines such as the Chinese hamster ovary (CHO) 
cell line are commonly used for producing recombinant 
human glycoproteins (Ghaderi et al., 2012). CHO cells 
have become a popular alternative to animals as an 
expression system for the efficient production of high 
quality recombinant proteins. Moreover, the glycosylation 
machinery of CHO cells is similar to that of human cells 
(Jeong et al., 2008; Stanley et al., 1996). The objective of 




MATERIALS AND METHODS 
 
Two 6-month-old male New Zealand rabbits were immunized using 
rHuEPO following a 30-day adaptation period. Five subcutaneous 
injections were administered in the scapular area of each rabbit, 
alternating between the right and left sides. The first immunization 
dose contained 84 µg rHuEPO and complete Freund’s adjuvant 
(Sigma-Aldrich, USA). Subsequent immunizations were performed 
after 7, 14, 21 and 28 days using rHuEPO (84 µg) and incomplete 
Freund’s adjuvant (Sigma-Aldrich, USA). Prior to immunization, 
blood was collected to determine the antibody titres. After the last 
immunization, indirect enzyme linked immuno sorbent assay 
(ELISA) was used to determine the rHuEPO antibody titres. 
Hyperimmune sera were obtained from animals with high antibody 
titre. The hyperimmune serum was stored at -20°C until required for 
further processing and purification. The antibodies were purified by 
affinity chromatography using a protein A-Sepharose CL-4B column 
(GE Healthcare Company, USA) according to the manufacturer’s 
instructions. The animals used in this study were treated in 
accordance with the guidelines recommended by Colégio Brasileiro 
de Experimentação Animal. The rHuEPO used in all experiments 
was EPREX
®
 by Janssen Cilag (Issy-les-Moulinaux, France). 
For performing the rHuEPO ELISA, polystyrene ELISA microtitre 
plates (NuncMaxiSorp
®
, NalgeNunc International, USA) were 
coated with rHuEPO (50 ng/well) and incubated overnight at 4°C. 
Next, the plates were washed with phosphate buffer saline with 
0.05% Tween 20 (PBS-T). Then, the wells were treated with 
blocking buffer (PBS containing 5% skim milk). Serial dilutions of 
the purified anti-rHuEPO pAb were incubated with rHuEPO-coated 





labelled with Ig-peroxidase conjugate (Sigma-Aldrich, USA) was 
added to the well. A substrate solution containing o-
phenylenediamine (0.4 mg/mL in 0.1 M citrate buffer, pH 5.0) and 
0.03% H2O2 was added to the ELISA plate and incubated for 15 
min. The reaction was stopped by adding H2SO4 (3 N), and the 
optical densities of the solutions were measured at 492 nm using 
the VICTOR
TM
 X5 Multilabel Plate Reader (Perkin Elmer, USA). 
Immunoblotting was performed to evaluate the specificity and 
sensitivity of the polyclonal antibodies. Rabbit preimmune sera and 
anti-EPO rabbit antibody (Sigma-Aldrich, USA) were used as the 
negative and the positive controls, respectively. rHuEPO solutions 
with concentrations of 0.05-0.3 µg per well were loaded onto 
sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-
PAGE) gels. For positive and negative controls, rHuEPO 
concentration of 1 µg per well was used. After electrophoresis, the 
rHuEPO proteins were transferred onto a nitrocellulose membrane 
(Millipore, USA) and then incubated at 37°C for 1 h with anti-
rHuEPO pAb that was diluted 1:10,000. Next, goat anti-rabbit Ig-
peroxidase conjugate (Sigma-Aldrich, USA) was added. The bands 
were visualized by using substrate/chromogen solution (0.6 mg 
diaminobenzidine, 0.03% nickel sulfate, 50 mM Tris-HCl at pH 8.0, 
and 0.03% H2O2). 
The Chinese hamster ovary (CHO)-K1 cell line was purchased 
from American Type Culture Collection and cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine 
serum and grown at 37°C in 5% CO2. Prior to transfection, the cells 
were seeded in 96-well plates (10
4
 cells/well) and incubated until 
80% confluence was reached. pTarget/EPO plasmid construct 
(Collares et al., 2012), pTARGET™ (Promega, USA) and pEGFP 
(Clontech, USA) were prepared for transfection according to the 
manufacturer’s instructions (Lipofectamine® 2000 Transfection 
Reagent - Life Technologies,USA). The cells were washed twice 
with PBS and incubated for 4 h with lipoplex mixture. After 24 h, the 
lipoplexes were removed by aspiration and the cells were fixed 
using methanol. The cells were then washed twice with PBS, 
blocked by using PBS with 10% fetal bovine serum and then 
incubated with anti-rHuEPO pAb for 2 h. After washing, the cells 
were incubated with goat anti-rabbit FITC conjugated antibodies 
(Invitrogen, USA) for 1 h. The fluorescent labels were visualized by 
using a fluorescence microscope (Olympus BX 71) with an 
excitation wavelength of 450 nm. CHO cells transfected with 
pEGFP and stained with a commercially available anti-EPO 
antibody (Sigma-Aldrich, USA) were used as positive controls; CHO 
cells transfected with pTARGET and stained with rabbit sera 
collected before immunization were used as negative controls. 
 
 
RESULTS AND DISCUSSION 
 
Several manufacturers produce anti-rHuEPO. However, 
commercially available anti-rHuEPO antibodies remain 
expensive, and the appearance of new competing 
manufacturers still has not led to price reduction and 
solution doping. Considering the high cost for production 
of monoclonal antibodies, the objective of this study was 
to produce cost-effective anti-rHuEPO pAb that can be 
used for immunoblotting and immunofluorescence 
assays. First, the anti-rHuEPO pAb was purified and 
used to perform indirect ELISA. The ELISA data indicated 
that rHuEPO could be efficiently detected using high 
antibody dilutions (1:10,000). To evaluate the anti-rHuEPO
 
 






Figure 1. rHuEPO detection by anti-recombinant human erythropoietin polyclonal antibody (rHuEPO 
pAb) in an immunoblotting assay. A, Molecular weight standard; B, positive control; C, anti-rHuEPO 






Figure 2. Immunofluorescence analysis of anti-rHuEPO pAb in CHO cells transfected with pTARGET/EPO. Panels: A, Transfection 
control (pEGFP); B, specific staining of CHO with commercial anti-EPO antibody; C, specific staining of CHO with anti-rHuEPO pAb 





pAb detection sensitivity, an immunoblotting assay was 
performed using various concentrations of rHuEPO. The 
anti-rHuEPO pAb (1:10,000) detection limit was 
determined to be 0.1 µg rHuEPO. Bands corresponding 
to the molecular weight of rHuEPO (30 kDa) were 
visualized (Figure 1C). Similar results were obtained with 
the commercial anti-EPO antibody (Figure 1B). In 
contrast, the rabbit sera obtained before immunization 
failed to detect rHuEPO (Figure 1D). Since the 
erythropoietin forms epoetin α and epoetin β are both 
produced in CHO cell lines and the basis for detecting 
rHuEPO doping relies on the glycosylation pattern of the 
protein (Franz, 2009; Girard et al., 2012; Reichel and 
Gmeiner, 2010), we hypothesized that anti-rHuEPO pAb 
could detect rHuEPO obtained from a eukaryotic 
expression system. To evaluate this hypothesis, 
pTARGET/EPO transfected CHO cells were stained with 
either anti-rHuEPO pAb (Figure 2C) or the commercial 
anti-EPO antibody (Figure 2B) to detect rHuEPO 
expression. The preimmunization sera failed to detect 
rHuEPO in pTARGET/EPO-transfected CHO cells (Figure 
2D) and on pTARGET transfected CHO cells (data not 
shown).To evaluate the transfection efficiency and 
rHuEPO expression capability of CHO cells, pEGFP was 
used as a transfection control (Figure 2A). 
The anti-rHuEPO pAb specifically detected rHuEPO by 
immunofluorescence staining and immunoblotting, which 
are methods that are commonly used to measure protein 
expression levels and to evaluate physiological roles of 
proteins (Ben-Gedalya et al., 2011; Brown et al., 1998; 
Valdenaire et al., 1999). Polyclonal antibody production 
offers a rapid and  cost-effective  alternative  to  commer- 
 
 




cially available monoclonal antibodies. In addition, 
polyclonal antibodies are known to recognize several 
epitopes on the same antigen and therefore detect 
antigens more efficiently than monoclonal antibodies. In 
conclusion, the anti-rHuEPO pAb produced in this study 
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